[1]张永庆a,尚立群a,苗 毅a,等.表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析[J].现代检验医学杂志,2017,32(06):78-80.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHANG Yong-qinga,SHANG Li-quna,MIAO Yia,et al.Analysis of the Correlation between Mutations of the Epidermal Growth Factor Receptor Gene and Pathological of Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(06):78-80.[doi:10.3969/j.issn.1671-7414.2017.06.001]
点击复制

表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年06期
页码:
78-80
栏目:
论著
出版日期:
2017-12-25

文章信息/Info

Title:
Analysis of the Correlation between Mutations of the Epidermal Growth Factor Receptor Gene and Pathological of Non Small Cell Lung Cancer
文章编号:
1671-7414(2017)06-078-03
作者:
张永庆a; 尚立群a; 苗 毅a; 陈瑞琳a; 杨淑梅a; 杜 洁b
陕西省人民医院a.呼吸内科; b.健康体检中心,西安 710068
Author(s):
ZHANG Yong-qinga; SHANG Li-quna; MIAO Yia; CHENRui-lina; YANG Shu-meia; DU Jieb
a.Respiratory Medicine; b.Health Examination Center,Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
表皮生长因子受体;  非小细胞肺癌;  基因突变;  靶向治疗
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.06.001
文献标志码:
A
摘要:
目的: 表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析。方法 选取陕西省人民医院2014年1月～2015年4月进行表皮生长因子受体(EGFR)检测的肺癌患者96例,比较不同类型非小细胞肺癌EGFR基因突变率。结果 基因突变敏感24例,其中12例突变位置L858R,10例突变位置19DEL,1例突变位置G719X和S768I,1例EML4-ALK融合。突变率29.17%,稍低于国际与国内的非小细胞肺癌EGFR基因突变敏感率30%的平均水平。结论 靶向治疗是针对非小细胞肺癌患者个体化治疗的有效手段,具有可靠的疗效,较轻的毒性和不良反应,将成为最有前途的治疗手段之一,该次研究结果略低于平均水平,考虑研究人群基数较少,需要提高常规检测的意识。
Abstract:
Abstract:Objective To analyze the correlation between pathological of non small cell lung cancer(NSCLC)and mutations of the epidermal growth factor receptor(EGFR)gene.Methods Selected 96 patients with lung cancer for EGFR mutation detection in Shaanxi Provincial People's Hospital from January 2014 and April 2015,comparison of different types ofNSCLC EGFR mutation rate.Results Gene mutation sensitivein 24 cases,in 12 cases and location of the mutation L858R,10 cases of mutation at position 19DEL,1 cases of mutation position G719X and S768I,1 cases EML4-ALK fusion.Mutation rate of 29.17%.Slightly lower than the international and domestic NSCLC epidermal growth factor receptor gene mutation sensitive rate of 30% of the average.Conclusion Target to treatment is aimed at the effective means for the treatment of NSCLC patients with individualized,has reliable efficacy,less toxicity and adverse reactions,will become oneof the most promising treatment,the study results below average,less attention to the base of the study population and need to raise awareness of routine testing.

参考文献/References:

[1] 王继灵,操乐杰.表皮生长因子受体检测在非小细胞肺癌中的临床意义[J].安徽医科大学学报,2011,46(6):608-611. Wang JL,Cao LJ.Clinical significance of epidermal growth factor receptor detection in non-small cell lung cancer[J].Acta Universitatis Medicinalis Anhui,2011,46(6):608-611.
[2] 中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟.晚期非小细胞肺癌分子靶向治疗专家共识(2013版)[J].中华结核和呼吸杂志,2014,37(3):177-183. Lung cancer group of Chinese medical association,China lung cancercontrol association.Expert consensus on target therapy for advanced non-smallcell lung cancer molecules(2013 edition)[J].Chinese Journal of Tuberculosis Respir Diseases,2014,37(3):177-183.
[3] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China 2015[J].CA Cancer J Clin,2016,66(2):115-132.
[4] 张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(2):83-86. Zhang L,Ren YN,Zeng TT,et al.Analysis of prognosis related factors in patients with advanced non-small cell lung cancer[J].Journal of ModernLaboratory Medicine,2016,31(2):83-86.
[5] 石远凯,孙 燕,丁翠敏,等.中国埃克替尼治疗非小细胞肺癌专家共识(2016年版)[J].中国肺癌杂志,2016,19(7):489-493. Shi YK,Sun Y,Ding CM,et al.China expert consensus on icotinib for non-small cell lung cancer treatment(2016 edition)[J].China Journal Lung Cancer,2016,19(7):489-493.
[6] Pao W, Miller V, Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101(36):13306-13311.
[7] Marchetti A,Martella C,Felicioni L,et al.EGFR mutations in non-smallcell lung cancer:analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment[J].J Clin Oncol,2005,23(4):857-865.
[8] Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological featuresassociated with epidermal growth factor receptor gene mutations in lung cancers[J].J Natl Cancer Inst,2005,97(5):339-346.
[9] 王玉丽,刘红雨,陈 军.非小细胞肺癌中EGFR基因状态的检测对EGFR-TKIs疗效的预测价值[J].中国肺癌杂志,2010,13(4):375-379. Wang YL,Liu HY,Chen J.The predictive value of EGFR-status in non-small cell lung cancer ratients treated with EGFR-TKIs[J].China Journal ofLung Cancer,2010,13(4):375-379. 收稿日期:2017-08-30 修回日期:2017-09-29

相似文献/References:

[1]陈 相a,陶国华a,周 峰a,等.叉头框蛋白J2在非小细胞肺癌组织 和癌旁组织中的表达及临床意义[J].现代检验医学杂志,2016,31(03):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
　CHEN Xianga,TAO Guo-huaa,ZHOU Fenga,et al.Expression and Its Clinical Significance of Forkhead Box J2 in Non-small Cell Lung Cancer Tissues and Paracancerous Tissues[J].Journal of Modern Laboratory Medicine,2016,31(06):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
[2]刘丽燕a,陈晓丹b,杨明夏c,等.外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义[J].现代检验医学杂志,2017,32(01):103.[doi:10.3969/j.issn.1671-7414.2017.01.028]
　LIU Li-yana,CHEN Xiao-danb,YANG Ming-xiac,et al.Significance of Tumor Abnormal Protein in Peripheral Blood in the Therapeutic Monitoring of Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(06):103.[doi:10.3969/j.issn.1671-7414.2017.01.028]
[3]喻 晶,李运雷,刘晓翌.非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究[J].现代检验医学杂志,2018,33(04):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
　YU Jing,LI Yun-lei,LIU Xiao-yi.Detection of Epidermal Growth Factor Receptor Gene Mutation in Different Sample Types of 238 Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
[4]林文科,吴吉芳,郑志昂.非小细胞肺癌患者血清miR-141及miR-224的表达及其临床意义[J].现代检验医学杂志,2018,33(02):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIN Wen-ke,WU Ji-fang,ZHENG Zhi-ang.Expression of Serum miR-141 and miR-224 in Patients with Non-Small Cell Lung Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(06):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[5]邝美华,陈意珊,石亚玲.血小板与淋巴细胞比值对非小细胞肺癌预后评估的Meta分析[J].现代检验医学杂志,2018,33(03):112.[doi:10.3969/j.issn.1671-7414.2018.03.028]
　KUANG Mei-hua,CHEN Yi-shan,SHI Ya-ling.Prognostic Value of Platelet to Lymphocyte Ratio in Non-Small Cell Lung Cancer:a Meta-analysis[J].Journal of Modern Laboratory Medicine,2018,33(06):112.[doi:10.3969/j.issn.1671-7414.2018.03.028]
[6]王　旋,崔立春,党升强.非小细胞肺癌放化疗联合靶向治疗对血清肿瘤标志物、免疫功能及CyclinD3水平影响的相关研究[J].现代检验医学杂志,2021,36(04):25.[doi:10.3969/j.issn.1671-7414.2021.04.006]
　WANG Xuan,CUI Li-chun,DANG Sheng-qiang.Effects of Radiotherapy and Chemotherapy Combined with Targeted Therapy onSerum Tumor Markers, Immune Function and CyclinD3 Level inNon-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):25.[doi:10.3969/j.issn.1671-7414.2021.04.006]
[7]苗留飞,杨 阳,余柏增,等.三代EGFR-TKI奥希替尼(AZD9291)耐药细胞系建立及耐药标志预测分析[J].现代检验医学杂志,2019,34(05):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]
　MIAO Liu-fei,YANG Yang,YU Bai-zeng,et al.Establishment of the Third Generation of EGFR-TKI Resistant CellLine and Resistance Gene Signature[J].Journal of Modern Laboratory Medicine,2019,34(06):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]

备注/Memo

备注/Memo:
基金项目:陕西省卫生计生委科研基金项目(项目编号:2016D036)。 作者简介:张永庆(1973-),男,本科,副主任医师,研究方向:肺癌的检测及治疗,E-mail:zhangyongqing656@163.com。 通讯作者:杜 洁(1983-),女,硕士,主治医师,研究方向:呼吸内科学,E-mail:dujie123@163.com。
更新日期/Last Update: 2017-12-26